Hepatology International

, Volume 9, Issue 3, pp 447–453 | Cite as

β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children

  • Ujjal Poddar
  • Upender Shava
  • Surender Kumar Yachha
  • Jaya Agarwal
  • Sheo Kumar
  • Sanjay S. Baijal
  • Anshu Srivastava
Original Article
First Online:
Received:
Accepted:

Abstract

Background/purpose

Thrombocytopenia due to hypersplenism precludes percutaneous liver biopsy in many cases of chronic liver disease (CLD). The aim of this study was to assess the efficacy of propranolol in correcting platelet counts (>100,000/mm3) to ensure percutaneous liver biopsy in children with CLD.

Methods

From January 2005 to December 2012, 51 consecutive children (mean age 11.5 ± 3.0 years, 34 boys) with CLD who needed liver biopsy but could not be done due to hypersplenism-related thrombocytopenia (platelets <100,000/mm3 and/or total leukocyte counts <4,000/mm3 with splenomegaly) were recruited and given a 4-week trial of long-acting propranolol (1.5–2 mg/kg/day). Hemodynamic parameters and splenic artery hemodynamics by Doppler ultrasound were recorded before and after the propranolol trial. Response to therapy was defined as improvement of platelet counts to ≥105/mm3.

Results

Thirty-two (62.7 %) children responded to propranolol therapy and their mean platelet counts increased from 57.5 ± 13.0 × 103 to 140.7 ± 43.3 × 103/mm3, p = 0.0001. Liver biopsy could be done in 29. While comparing responders with non-responders, baseline spleen size (7.4 ± 3.3 vs. 12.7 ± 4.5 cm, p = 0.0001) and platelet counts (57.5 ± 13.0 × 103 vs. 39.5 ± 14.5 × 103, p = 0.0001) were found to be significant. ROC curve suggested a cut-off value of ≤8.5 cm of spleen and ≥53,000 platelets as predictors of response. With propranolol, mean arterial pressure and spleen size reduced (p < 0.05) and splenic artery resistance increased significantly (p = 0.005) in responders.

Conclusions

Propranolol corrects thrombocytopenia and makes liver biopsy possible in almost two-thirds of cases by reducing splenic sequestration through splenic artery vasoconstriction. The baseline spleen size and platelet counts determine the effectiveness of therapy. A trial of β-blocker is worth carrying out in cases where liver biopsy is contraindicated due to hypersplenism-related thrombocytopenia.

Keywords

Propranolol Portal hypertension Splenomegaly Liver biopsy 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

We acknowledge the contribution of Dr. Jagadeesh R, Dr. Anuj Thakral, Dr. Madhvi Verma for helping us in facilitating the Doppler study. This paper was presented at the 21st United European Gastroenterology Week (UEGW 2013), Berlin, Germany, October 12–16, 2013.

Compliance with ethical requirements and Conflict of interest

Informed consent was obtained from parents of all participating children. All procedures performed in this study were in accordance with the ethical standards of the institute and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Ujjal Poddar, Upender Shava, Surender K Yachha, Jaya Agarwal, Sheo Kumar, Sanjay S Baijal, and Anshu Srivastava declare that they have no conflict of interest and ethical standards were maintained in this study.

References

  1. 1.
    Poddar U, Thapa BR, Rao KL, Singh K. Etiological spectrum of esophageal varices due to protal hypertension in Indian children: is it different from the West? J Gastroenterol Hepatol 2008;23:1354–1257PubMedCrossRefGoogle Scholar
  2. 2.
    Arora NK, Arora S, Ahuja A, Mathur P, Maheshwari M, Das MK, et al. Alpha 1 antitrysin deficiency in children with chronic liver disease in north India. Indian Pediatr 2010;47:1015–1023PubMedCrossRefGoogle Scholar
  3. 3.
    Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnotic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol 2012;10:417–421.e1–e2 doi:  10.1016/j.cgh.2011.11.030. Epub 2011 Dec 15
  4. 4.
    Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Members of the APASL Working Party on Portal Hypertension, et al. Noncirrhotic portal fibrosis/idiopathic portal hyepertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007;1:398–413 doi: 10.1007/s12072-007-9010-9 Epub 2007 Sep 11PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003;326:111–116PubMedCrossRefGoogle Scholar
  6. 6.
    Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936–2939PubMedCrossRefGoogle Scholar
  7. 7.
    El-Khishen MA, Henderson JM, Millikan WJ, Kutner MH, Warren WD. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet 1985;160:233–238PubMedGoogle Scholar
  8. 8.
    McCormick PA, Walker S, Benepal R. Hypersplenism is related to age of onset of liver disease. Ir J Med Sci 2007;176:293–296PubMedCrossRefGoogle Scholar
  9. 9.
    Krishna YR, Yachha SK, Srivastava A, Negi D, Lal R, Poddar U. Quality of life in children managed for extrahepatic portal venous obstruction. J Pediatr Gastroenterol Nutr 2010;50:531–536 doi: 10.1097/MPG.0b013e3181b6a55d PubMedGoogle Scholar
  10. 10.
    Aoki Y, Hiari K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis. Kinetics of Indium-111 tropolone labeled platelets. Eur J Nuclear Med 1993;20:123–129CrossRefGoogle Scholar
  11. 11.
    Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “Hypersplenic” thrombocytopenia. J Clin Invest 1966;45:645–657PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Sakai K, Iwao T, Oho K, Toyonaga A, Sata M. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. J Gastroenterol 2002;37:112–118PubMedCrossRefGoogle Scholar
  13. 13.
    Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices—a prospective controlled randomized trial. Endoscopy 1982;14:4–5PubMedCrossRefGoogle Scholar
  14. 14.
    Taylor KJ, Holland S. Doppler ultrasound. I. Basic principles, instrumentation and pitfalls. Radiology 1990;174:297–307PubMedCrossRefGoogle Scholar
  15. 15.
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy Hepatology 2009;49:1017–1044 doi: 10.1002/hep.22742 CrossRefGoogle Scholar
  16. 16.
    Scheimann AO, Barrios JM, Al-Tawil YS, Gray KM, Gilger MA. Percutaneous liver biopsy in children: impact of ultrsonography and spring-loaded biopsy needles. J Pediatr Gastroenterol Nutr 2000;31:536–539PubMedCrossRefGoogle Scholar
  17. 17.
    Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP. Comparison of effects of a cardioselective and a nonselective β-blocker on portal hypertension in patient with cirrhosis. Hepatology 1982;2:528–531PubMedCrossRefGoogle Scholar
  18. 18.
    Westaby D, Bihari DJ, Gimson AE, Crossley IR, Williams R. Selective and non-selective β receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984;25:121–124PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kroeger R, Groszmann RJ. The effect of selective blockade of β-2 adrenergic receptors on portal and systemic hemodynamics in portal hypertensive rat model. Gastroenterology 1985;88:896–900PubMedGoogle Scholar
  20. 20.
    Bolognesi M, Sacerdoti D, Merkel C, Gerunda G, Maffei-Faccioli A, Angeli P, et al. Splenic Doppler impedence indices: influence of different portal hemodynamic conditions. Hepatology 1996;23:1035–1040PubMedCrossRefGoogle Scholar
  21. 21.
    Sacerdoti D, Gaiani S, Buonamico P, Merkel C, Zoli M, Bolondi L, et al. Interobserver and interequipment variability of hepatic, splenic and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. J Hepatol 1997;27:986–992PubMedCrossRefGoogle Scholar
  22. 22.
    de Oliveira CA, de Sa RA, Velarde LG, Monteiro VN, Netto HC. Doppler velocity of the ophthalmic artery. J Ultrasound Med 2012;31:879–884PubMedGoogle Scholar
  23. 23.
    Hollis B, Mavrides E, Campbell S, Tekay A, Thilaganathan B. Reproducibility and repeatability of transabdominal uterine artery Doppler velocimetry between 10 and 14 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:593–597PubMedCrossRefGoogle Scholar
  24. 24.
    Bolognesi M, Sacerdoti D, Merkel C, Gatta A. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. J Ultrasound Med 1994;13:945–952PubMedGoogle Scholar
  25. 25.
    Iwao T, Oho K, Sakai T, Sato M, Nakano R, Yamawaki M, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 1998;28:847–855PubMedCrossRefGoogle Scholar
  26. 26.
    Berzigotti A, Rinaldi MF, Magalotti D, Morelli MC, Zappoli P, Andreone P, et al. Primary prophylaxis with nadolol in cirrhotic patients: doppler patterns of splanchnic hemodynamics in good and poor responders. J Hepatol 2006;44:310–316PubMedCrossRefGoogle Scholar
  27. 27.
    Sabba C, Buonamico P, Vendemiale G, Berardi E, Antonica G, Palmieri V, et al. Hemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperemia in patients with cirrhosis. Eur J Gastroenterol Hepatol 2001;13:163–169PubMedCrossRefGoogle Scholar
  28. 28.
    Landolifi R, Leone G, Fedeli G, Storiti S, Laghi F, Bizzi B. Platelet associated IgG in acute and chronic hepatic disease. Scand J Hematol 1980;25:417–422CrossRefGoogle Scholar
  29. 29.
    Asenia P, Frangi M, Beati C, Vertemati M, Romani F. Is thrombocytopenia in liver failure dependent on an inadequate synthesis of thrombopoietic stimulating factor by the liver? Med Hypothesis 1988;26:217–219CrossRefGoogle Scholar
  30. 30.
    Alvarez OA, Lopera GA, Patel V, Encarnacion CE, Palmaz JC, Lee M. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol 1996;91:134–137PubMedGoogle Scholar
  31. 31.
    Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-Kolbl C, Fleischer J, et al. Course of platelet counts in cirrhotic patients after implantation of transjugular intrahepatic portosystemic shunt- a prospective, controlled study. J Hepatol 1999;30:254–259PubMedCrossRefGoogle Scholar
  32. 32.
    Puttini M, Marni A, Montes F, Belli L. Effect of portosystemic shunt on hypersplenism: clinical study in 129 patients with cirrhosis. Am Surg 1979;45:444–448PubMedGoogle Scholar
  33. 33.
    Marni A, Trojsi C, Belli L. Distal splenorenal shunt: hemodynamic advantage over total shunt and influence on clinical status, hepatic function and hypersplenism. Am J Surg 1981;142:372–376PubMedCrossRefGoogle Scholar
  34. 34.
    Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993;18:309–314PubMedCrossRefGoogle Scholar
  35. 35.
    Nio M, Hayashi Y, Sano N, Ishii T, Sasaki H, Ohi R. Long-term efficacy of partial splenic embolization in children. J Pediatr Surg 2003;38:1760–1762PubMedCrossRefGoogle Scholar
  36. 36.
    Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:1–31 doi: 10.1002/hep.23584 CrossRefGoogle Scholar
  37. 37.
    Poddar U, Thapa BR, Puri P, Girish CS, Vaiphei K, Vashishta RK, et al. Non-cirrhotic portal fibrosis in children. Indian J Gastroenterol 2000;19:12–13PubMedGoogle Scholar
  38. 38.
    Poddar U, Thapa BR, Vashishta RK, Girish CS, Singh K. Congenital hepatic fibrosis in Indian children. J Gastroenterol Hepatol 1999;14:1192–1196PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2014

Authors and Affiliations

  • Ujjal Poddar
    • 1
  • Upender Shava
    • 1
  • Surender Kumar Yachha
    • 1
  • Jaya Agarwal
    • 1
  • Sheo Kumar
    • 2
  • Sanjay S. Baijal
    • 2
  • Anshu Srivastava
    • 1
  1. 1.Department of Pediatric GastroenterologySanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)LucknowIndia
  2. 2.Department of RadiologySanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)LucknowIndia

Personalised recommendations